B12019 and Neulasta are formulations of pegfilgrastim, a pegylated form of the granulocyte colony-stimulating factor analog filgrastim, which mitigates the negative effects of chemotherapy on the ...

Biocon Biologics has gained approval from the US Food and Drug Administration (FDA) for the intravenous use of Jobevne ...

The FDA has approved Sandoz’s pegfilgrastim biosimilar ... market since last year and is a granulocyte colony stimulating factor (GCSF) class drug. Approval of Ziextenzo was based on a dossier ...

Biocon Biologics has received the Food and Drug Administration’s green light for Jobevne (bevacizumab-nwgd), a biosimilar ...

Biocon's stock price increased almost 4 per cent in the early trading session on 11 April after the company’s subsidiary ...

In 2023, bevacizumab sales in the U.S. were around $2.0 billion. Biocon Biologics serves over 5 million patients each year ...

Biocon Biologics Ltd today announced that the U.S. FDA has approved Jobevne™ (bevacizumab-nwgd), a biosimilar Bevacizumab for ...

Bengaluru: Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd, has announced that the U.S. Food and Drug Administration ...